We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Δ
